Skip to content

CFDs are leveraged products. CFD trading may not be suitable for everyone and can result in losses that exceed your deposits, so please ensure that you fully understand the risks involved. CFDs are leveraged products. CFD trading may not be suitable for everyone and can result in losses that exceed your deposits, so please ensure that you fully understand the risks involved.

Fever-Tree share price: what’s the latest ahead of its January trading update?

The premium producer of carbonated mixers will release a trading update next week, with analysts from HSBC and Liberum Capital reiterating their ‘buy’ ratings in January.

trader stock Source: Bloomberg

Fever-Tree is up more than 10% this week ahead of its trading update on January 21 (Tuesday), with the company reporting impressive sales growth over the last four years - a trend the drinks maker hopes to continue in its results next week.

In its last trading update in November, the drinks maker reported sales growth across all four operating regions and expects to record double-digit revenue growth in 2019.

‘We continue to see growth across all four regions,’ Fever-Tree CEO Tim Warrillow said. ‘Indeed, sales accelerated in our key growth markets of the US and Europe.’

‘Fever-Tree's progress in the US is particularly encouraging and the signing of a US bottling partner is a further step in building our operations in this exciting market,’ he added.

Fever-Tree is trading at £20.97 a share as of 15:50 GMT on Wednesday.

Looking to trade Fever-Tree? Open a live or demo account with IG.

Will Fever-Tree hit revenue targets?

Following a strong performance across all four regions, the company now expects to generate total revenue of between £266 million to £268 million, representing 12% - 13% growth, with margin forecasts unchanged.

Analysts had been forecasting sales of between £272 million to £275 million in 2019.

Investors will be eager to see if the company can meet expectations next week, with a strong set of results capable of sending its share price higher.

HSBC and Liberum Capital reiterate ‘buy’ rating

Analysts from HSBC and Liberum Capital reiterated their ‘buy’ rating for the stock in January ahead of the company’s latest trading update.

Both left their previous price targets for the stock unchanged, with HSBC and Liberum Capital issuing targets of £33 and £28.25 respectively.

Based on the stock trading at £20.97 the pair believe it has a potential upside of 34.7% and 57.4%.

You can go long or short Fever-Tree with IG using derivatives like CFDs.

IGA, may distribute information/research produced by its respective foreign affiliates within the IG Group of companies pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the research is distributed in Singapore to a person who is not an Accredited Investor, Expert Investor or an Institutional Investor, IGA accepts legal responsibility for the contents of the report to such persons only to the extent required by law. Singapore recipients should contact IGA at 6390 5118 for matters arising from, or in connection with the information distributed.

The information/research herein is prepared by IG Asia Pte Ltd (IGA) and its foreign affiliated companies (collectively known as the IG Group) and is intended for general circulation only. It does not take into account the specific investment objectives, financial situation, or particular needs of any particular person. You should take into account your specific investment objectives, financial situation, and particular needs before making a commitment to trade, including seeking advice from an independent financial adviser regarding the suitability of the investment, under a separate engagement, as you deem fit.

No representation or warranty is given as to the accuracy or completeness of this information. Consequently, any person acting on it does so entirely at their own risk. Please see important Research Disclaimer.

Please also note that the information does not contain a record of our trading prices, or an offer of, or solicitation for, a transaction in any financial instrument. Any views and opinions expressed may be changed without an update.

Seize a share opportunity today

Go long or short on thousands of international stocks.

  • Increase your market exposure with leverage
  • Get spreads from just 0.1% on major global shares
  • Trade CFDs straight into order books with direct market access

Live prices on most popular markets

  • Forex
  • Shares
  • Indices

Prices above are subject to our website terms and agreements. Prices are indicative only. All shares prices are delayed by at least 15 mins.

Prices above are subject to our website terms and agreements. Prices are indicative only. All shares prices are delayed by at least 20 mins.

The Momentum Report

Get the week’s momentum report sent directly to your inbox every Tuesday for FREE. The Week Ahead gives you a full calendar of upcoming key events to monitor in the coming week, as well as commentary and insight from our expert analysts on the major indices to watch.

For more info on how we might use your data, see our privacy notice and access policy and privacy webpage.

You might be interested in…

Find out what charges your trades could incur with our transparent fee structure.

Discover why so many clients choose us, and what makes us a world-leading provider of CFDs.

Stay on top of upcoming market-moving events with our customisable economic calendar.